Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01334151 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes
A Phase 1 study, sponsored by Biodel.
- Completed
- Registry status
- Phase 1
- Development phase
- 13
- Enrollment target
NCT01334151 is a Phase 1 study that has completed, run by Biodel. The registered enrollment target is 13 participants.
The verdict
NCT01334151, a Phase 1 study, has completed, sponsored by Biodel.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 13 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the speed of absorption and onset of action of BIOD-105 and BIOD-107 and compare them to Humalog®.
Interventions
- DRUG Insulin LISPRO
- DRUG recombinant human insulin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2011-03 |
| Est. Completion | 2011-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01334151
The ClinicalTrials.gov registry entry for NCT01334151 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 13 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biodel, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Insulin LISPRO is the first listed.
NCT01334151 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01334151 about?
NCT01334151 is a clinical study titled "Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes". The primary objective of this study is to assess the speed of absorption and onset of action of BIOD-105 and BIOD-107 and compare them to Humalog®.
What is the current status of trial NCT01334151?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2011-03. Estimated completion is 2011-08.
What interventions are being tested in trial NCT01334151?
The interventions under investigation include: Insulin LISPRO (DRUG), recombinant human insulin (DRUG).
Who is sponsoring clinical trial NCT01334151?
This trial is sponsored by Biodel, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.